EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study

Nico Gagelmann iD, Dirk-Jan Eikema, Linda Koster, Tanja Netelenbos, Andrew McDonald, Anne-Marie Stoppa, Roland Fenk, Achilles Anagnostopoulos, Gwendolyn van Gorkom iD, Eric Deconinck iD, Claude-Eric Bulabois, Michel Delforge und 13 weitere

European Journal of Haematology · 2023

DOI: 10.1111/ejh.13981 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Nico Gagelmann und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No adequate data exist on the impact of multiple myeloma (MM) with extramedullary disease (EMD) after autograft and maintenance therapy.

Methods

We identified 808 patients with newly diagnosed MM who received first autograft, of whom 107 had EMD (83 paraskeletal and 24 organ involvement), and who had been reported to the EBMT registry December 2018. Distribution according to type of involvement was similar between the treatment groups ( p = .69). For EMD, 46 (40%) received thalidomide, 59 (51%) lenalidomide, and 11 (10%) bortezomib.

Results

The median follow‐up from maintenance start was 44 months. Three‐year progression‐free survival (PFS) was 52% (48%–57%) for no EMD, 56% (44%–69%) for paraskeletal involvement, and 45% (22%–68%) for organ involvement ( p = .146). Early PFS (within first year) appeared to be significantly worse for organ involvement (hazard ratio, 3.40), while no significant influence was found after first year from maintenance start. Three‐year overall survival (OS) was 81% (77%–84%), 88% (80%–96%), and 68% (47%–89%; p = .064), respectively. With thalidomide as reference, lenalidomide was significantly associated with better PFS and OS, whereas bortezomib appeared to improve outcome specifically in EMD.

Conclusion

Lenalidomide maintenance is standard of care for MM without EMD, whereas extramedullary organ involvement remains a significant risk factor for worse outcome, especially for early events after maintenance start.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansBortezomibLenalidomideThalidomideAutograftsTransplantation, AutologousAntineoplastic Combined Chemotherapy ProtocolsDexamethasone

Stichwörter der Autor:innen

extramedullary diseasemaintenancemyeloma

Substanzen

BortezomibLenalidomideThalidomideDexamethasone

Autor:innen und Institutionen

  • Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Statistics, Leiden University Medical Centre, Leiden, The Netherlands.
  • EBMT Data Office, Leiden, The Netherlands.
  • Haga Teaching Hospital, Hague, The Netherlands.
  • Alberts Cellular Therapy, Pretoria East Hospital, Pretoria, South Africa.
  • Institut Paoli Calmettes, Marseille, France.

ORCID-Profile: Nico Gagelmann, Gwendolyn van Gorkom, Eric Deconinck, Ali Zahit Bolaman, Patrick J Hayden

Zitieren

APA

Gagelmann, N., Eikema, D. J., Koster, L., Netelenbos, T., McDonald, A., Stoppa, A. M., Fenk, R., Anagnostopoulos, A., van Gorkom, G., Deconinck, E., Bulabois, C. E., Delforge, M., Bunjes, D., Arcese, W., Reményi, P., Itälä-Remes, M., Thurner, L., Bolaman, A. Z., Nabil, Y., …, & Yakoub-Agha, I. (2023). Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study. European Journal of Haematology. https://doi.org/10.1111/ejh.13981

Vancouver

Gagelmann N, Eikema DJ, Koster L, Netelenbos T, McDonald A, Stoppa AM, et al. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study. European Journal of Haematology. 2023. doi:10.1111/ejh.13981

BibTeX
@article{Gagelmann2023,
  author = {Gagelmann, Nico and Eikema, Dirk-Jan and Koster, Linda and Netelenbos, Tanja and McDonald, Andrew and Stoppa, Anne-Marie and Fenk, Roland and Anagnostopoulos, Achilles and van Gorkom, Gwendolyn and Deconinck, Eric and Bulabois, Claude-Eric and Delforge, Michel and Bunjes, Donald and Arcese, William and Reményi, Péter and Itälä-Remes, Maija and Thurner, Lorenz and Bolaman, Ali Zahit and Nabil, Yafour and Lund, Johan and Labussière-Wallet, Hélène and Hayden, Patrick J and Beksac, Meral and Schönland, Stefan and Yakoub-Agha, Ibrahim},
  title = {Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.13981}
}
Kostenlos starten →